SUMMARY
Hypnotic agents which facilitate the production and maintenance of sleep in insomniacs can be used also for transient insomnia occurring for extraneous reasons in those who normally sleep well [1] . It has therefore become common practice to offer patients a hypnotic agent on the evening before surgery [2] . A hypnotic selected for this purpose should be without adverse effects and short-acting, leaving the patient without residual preoperative sequelae. It is customary to prescribe benzodiazepines for hypnosis on the night before operation.
Zopiclone is a cyclopyrrolone but has many of the characteristics associated normally with a benzodiazepine: anticonvulsant, myorelaxant, antiaggressive, sedative-hypnotic and "anticonflict" [3] . It is short-acting with a half-life of 3.5-5 h [4] . Examination of the dose-response profile for zopiclone in insomniac patients indicates that maximum benefit in terms of both sleep induction and maintenance can be obtained at a dose of 7.5 mg [5] . This dose has been shown to have some advantages over triazolam [6] , nitrazepam [7] and flurazepam [8] and to be comparable with temazepam [9] . Residual effects have been shown to be less with zopiclone than with nitrazepam [10, 11] , a dose of 7.5 mg producing only marginal hangover effects whilst a dose of 5 mg results in no detectable effects at 12 h [12] . A dose of 7.5 mg was considered optimal, however, as it produces significant hypnotic effect with minimum residual impairment [11, 5] . There is evidence that memory may be impaired in the morning after administration with this dose but that this impairment is less with zopiclone than with some benzodiazepines [5] .
Zopiclone has been used as a hypnotic on the night before operation and been shown to be comparable with lormetazepam and midazolam using subjective assessment of quality of sleep and psychomotor performance, but no placebo control was used [13] . However, as temazepam is also used frequently for this type of hypnotic we have compared zopiclone 7.5 mg with temazepam 20 mg and placebo, assessing subjective and objective effects, including psychomotor performance and memory.
PATIENTS AND METHODS
After obtaining approval from the Hospital Ethics Committee, we studied 60 patients [14] of ASA grades I and II, aged 18-65 yr. Exclusion criteria included evidence of clinically relevant concurrent disease, a history of drug or alcohol abuse and concurrent drug therapy with centrally acting drugs or those known to interact with the trial drugs.
Eligible patients were recruited from the afternoon surgical lists of those presenting for minor head and neck surgery (e.g. dental extraction, nasal polypectomy, submucous resection of turbinates, tonsillectomy, cyst removal, etc.). After admission the evening before surgery, the patients were invited to participate in the study, a full explanation was given and written consent obtained. The psychological test battery was completed for the first time during this initial interview which lasted approximately 20 min.
A computer-generated, randomized code was used to determine to which of the three drug regimens the patient was allocated. The interviewer and patient were blind to the allocation of the treatment, the code for which was not available to the investigator until after completion of all data collation. Each group received either zopiclone 7.5 mg, temazepam 20 mg or placebo. To overcome the problem of the different presentation of each drug, a double-dummy technique was used with each patient receiving both a capsule and a tablet, either one or both of which was placebo. The trial medications were administered to the patient by the night nursing staff at about 22:00, this being the usual time for the administration of night hypnotics on the ward.
Between 08:00 and 09:00 the following morning, the patients were interviewed about their night's sleep using a modification of the Leeds sleep evaluation questionnaire [15] . The psychological test battery was then completed for the second time and the presence or absence of spontaneously reported side effects was noted.
The test battery was designed to explore changes in performance and comprised five standard psychometric measures, as detailed below, all with established use in psychological experimentation and assessment of drug effects. Of these tests three were objective measures of performance and two measured the patients' subjective experiences.
Objective measures
Critical flicker fusion threshold (CFFT) [16, 17] was used to detect CNS depression as it is thought widely to be an objective measure of cortical arousal. The standard hand-held Leeds psychomotor tester was used to determine the threshold at which a light flickering at an increasing rate is perceived as being constant and, conversely, when the frequency is decreasing the threshold at which a flicker can be detected. The score used was the mean of three of each type of trial. Ambient light, illumination and viewing distance were controlled throughout the testing sessions. [18] was used to assess short-term spatial recall. The patient was presented with a card on which were drawn 15 simple everyday objects and was allowed 1 min in which to study the card. The card was removed and the patient was asked to recall as many of these objects as possible in 2 min. The score was the number of objects recalled correctly, the value used in the analysis was the difference between evening baseline and morning test scores.
Object recall test (ORT)
Paired associates task {PAT) was used to assess short-term semantic recognition (after the Wechsler memory scale [19, 20] ). The patient listened through headphones to a presentation of a list of 10 pairs of words; in six pairs the two words have an obvious association and in the remaining four there was no association. Recognition was tested immediately by presenting the first word of each pair followed by four words, the task being to identify which of those four was in the original pair. The score was derived from the number of words identified correctly, the non-associated words scoring double (maximum 14 points); the value used in the analysis was the difference between evening baseline and morning test scores.
Subjective measures
Visual analogue scales (VAS) [21] were used to monitor levels of anxiety and mood. For each question the subject was required to draw a perpendicular mark through an ungraded 100-mm line, the ends of which were labelled with bipolar adjectives. The score for each VAS was derived by measuring the position of the mark to the nearest mm; the value used in the analysis was the difference between evening baseline and morning test scores. By way of instruction patients were asked to do a demonstration VAS describing their height [22] before completing the first VAS battery.
Sleep questionnaire (SQ) [15] . Patients were asked to complete a modification of the Leeds sleep evaluation questionnaire (LSEQ) which utilizes VAS [23] to measure three of the four LSEQ subjective dimensions of sleep: ease of getting to sleep, quality of sleep, ease of waking. It also requires the patient to estimate the time taken to get to sleep and the length of time slept.
Statistical methods
The raw data analysis was conducted on the SPSS statistical package running on a Novell Netware system through a Mertec 486DX PC computer. The times from the questionnaire and the results from the CFFT task were analysed using ANOVA (in the case of CFFT with the baseline as covariate) and a paired t test where appropriate. The remaining nonparametric data were analysed using a KruskalWallis analysis of variance or Mann-Whitney test, as appropriate.
RESULTS
A total of 63 patients were recruited into the study, but three were subsequently excluded (two withdrew, the third took an antihistamine). The three groups were comparable in age, height, weight and gender; less than 50% of subjects (25) were smokers and 25 % of those smoked less than 10 cigarettes per day (table I) .
Objective measures
Of the three objective measures only the results of the CFFT showed a statistically significant overall treatment effect (P < 0.05). The placebo group showed a minor improvement in the morning assessment, but this diurnal variation was not apparent in either of the two active drug groups (table II) . Further analysis showed a significant difference between zopiclone and placebo (P < 0.01), but not between zopiclone and temazepam (P > 0.05).
There was no significant difference between the groups in the scores for the memory tasks (table III) . However, in the ORT, less than 33 % of patients given zopiclone and just less than 50% of those given temazepam showed an improvement in the morning test compared with nearly 66 % of those given placebo.
Subjective measures
Mean scores indicated a reduction in anxiety and an increase in confusion for all three groups in the morning compared with the previous evening, whilst the placebo group alone recorded an increase in depression (table IV)-The groups were similar in the level of tiredness reported, both retrospectively at waking, and at the time of interview. There was no significant difference between groups in any of the subjective measures. Although there was no significant difference in the measured anxiety, only 25 % of the zopiclone group (five) recorded an increase in anxiety in the morning compared with more than 50% of each of the other groups (11 in the temazepam and 12 in the placebo group).
On two of three dimensions of the SQ there was a significant difference between groups (table V). Getting to sleep was reported to be most difficult by patients who had received placebo, whilst those receiving zopiclone or temazepam recorded similar scores (P < 0.001). Further analysis showed a significant difference between the zopiclone and placebo groups (P < 0.001) but not between those given zopiclone or temazepam (P > 0.05). Quality of sleep was also comparable between those given the active drug and poorer in those given placebo (P < 0.05). Further analysis showed a significant difference between the zopiclone and placebo groups (P < 0.05), but not between those given zopiclone or temazepam (P > 0.05). The placebo group reported the least difficulty in waking but there was no significant difference between groups (P > 0.05).
There was a significant difference between groups in the amount of time they reported having taken to fall asleep (P < 0.05) and the length of time slept (P < 0.01). In each of these cases further analysis confirmed that the scores from the zopiclone group were significantly better than those from the placebo group (P < 0.01 and P < 0.005, respectively) but not different from the temazepam group (P > 0.05).
DISCUSSION
It would seem that zopiclone is an effective hypnotic on the night before operation in reducing the length of time taken to fall asleep and increasing the duration of sleep. Furthermore, patients given zopiclone appear to experience greater ease of getting to sleep and superior quality of sleep compared with those given placebo. Both groups given an active drug had mean sleep scores of more than 50. As these scales require the patient to compare the night's sleep before operation with their normal night's sleep, scores greater than 50 may suggest that it was easier and quicker to get to sleep than usual. A linear interpretation of individual responses to VAS may be inappropriate.
The scores for patients given zopiclone were comparable with those of the patients given temazepam throughout the study. This accords with the work of Rettig and colleagues [13] who found zopiclone was comparable with lormetazepam and midazolam when used in this context; however the lack of a placebo control restricts interpretation of their results. These findings accord with the review by Jonas and colleagues [24] which showed that zopiclone and zolpidem were in many ways indistinguishable from benzodiazepine hypnotics. There was a trend for both these groups of patients to report that waking was more difficult than usual. There were no clinically significant hangover effects with either of the active drugs, although it may be -that they masked diurnal improvement in performance more apparent in the placebo group. There was no evidence that either of the active drugs affected the mood of the patients, as measured by VAS. But two trends were apparent: the placebo group tended to score higher on depression, possibly because of the poor night's sleep, and fewer patients given zopiclone recorded an increase in anxiety in the morning compared with the other two groups.
It could be argued that these measures are dependent on the patient's ability to estimate the passage of time when in a drugged state and loss of critical judgement may be a side effect of centrally acting drugs. However, insomnia is a subjective experience and there is wide individual variation on acceptable sleep variables. The subjective estimates of "time to go to sleep" and "sleep duration" by normal subjects have shown good correlation with objective recordings [25] and subjective measurement is a useful means of assessing the sleep facilitation properties of different hypnotics.
When measuring dimensions of effect, subject preselection can minimize the effects of the interaction between personality and performance [26] . This sample may not have included those patients who would have been inclined to extreme preoperative insomnia. The study criteria prevented the inclusion of those who demonstrated excessive anxiety at the initial interview and those whose possible diagnoses included cancer.
It may be noted that many subjects claimed at the preliminary interview to be "good sleepers" and doubted their need for chemical assistance. However, laboratory reports have demonstrated the "first night" effect, where environmental changes have disrupted sleep patterns [27] . An increase in the perceived time taken to get to sleep and more nocturnal awakenings are typical symptoms. Weinman [27] has attributed these alterations to many factors, including unusual noises, changes in routine, anxiety and pain or discomfort; each of these may be associated with the preoperative night.
We conclude that zopiclone is an effective singledose hypnotic, comparable with temazepam, and may provide a suitable alternative to benzodiazepines.
